Evotec drops after Q1 miss
** Shares in Evotec EVTG.DE are down around 7% in early Frankfurt trade after the German biotech company reported worse than expected Q1 results ** "Numbers below expectations," a local trader says, adding though the 2025 outlook was confirmed ** The stock, down 9% YTD, is at the bottom of the German mid-cap index .MDAX (Reporting by Simon Ferdinand Eibach) ((Simonferdinand.eibach@thomsonreuters.com))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases